Todd Correll presenting at HIV Glasgow 2022. Image by Alan Donaldson Photography.At the International Congress on Drug Therapy in HIV Infection (HIV Glasgow), the drug company MSD (Merck in the US) presented the first detailed data on the unexpected side effects of its first-in-kind anti-HIV drug, islatravir.
MSD showed that it should be possible to take a smaller daily dose of the drug – 0.25 milligrams (mg) – without it causing the falls in CD4 cell, B-cell and total lymphocyte (white cell) counts that halted its clinical development almost a year ago.
However, as MSD announced last month, the larger doses and novel formulations of islatravir that held out the promise of monthly or even yearly dosing – and of a revolution in HIV prevention – won’t now be developed.
Read the full story at Aidsmap.
Source : Aidsmap
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.